Biocept

Biocept EBITDA Margin

The EBITDA Margin of Biocept (BIOCQ) as of Nov 20, 2026 is -123.69 %. In the previous year, EBITDA Margin was -3.93 % — a change of 3,044.75% (lower).

EBITDA Margin

-123.69 %

YoY

3,044.75%

Last updated:

EBITDA Margin of Biocept is 2022 -123.69 % . EBITDA Margin of Biocept was 2021 -3.93 % . It decreases by 3,044.75% lower compared to the previous year.

The Biocept EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2015
-2,690.16 USD
Jan 1, 2016
-559.94 USD
Jan 1, 2017
-417.55 USD
Jan 1, 2018
-746.46 USD
Jan 1, 2019
-417.05 USD
Jan 1, 2020
-56.33 USD
Jan 1, 2021
-3.93 USD
Jan 1, 2022
-123.69 USD
The Biocept EBITDA Margin history
YEAREBITDA MarginYoY
-123.69 %+3,044.75%
-3.93 %-93.02%
-56.33 %-86.49%
-417.05 %-44.13%
-746.46 %+78.77%
-417.55 %-25.43%
-559.94 %-79.19%
-2,690.16 %-74.79%
-10,669.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

EBITDA Margin of Biocept is -123.69 % in 2022.

EBITDA Margin of Biocept changed from -3.93 % to -123.69 %, representing a 3,044.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Biocept since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biocept

All Key Metrics — Biocept